Organization
Shandong First Medical University and Shandong Academy of Medical Science
9 abstracts
Abstract
Efficacy and surgical safety of sequential surgical resection after neoadjuvant chemoimmunotherapy for unresectable stage III NSCLC.Org: Department of Internal Medicine Oncology, Shandong First Medical University and Shandong Academy of Medical Science, Shandong Provincial Institute of Cancer Prevention and Treatment,
Abstract
First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics of BY101298: Initial report from dose escalation cohort.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong University of Traditional Chinese Medicine Affiliated Hospital, Jinan, China National Biotec Group, Shandong Suncadia Medicine,
Abstract
Effect of continued immunotherapy on survival of extensive-stage small cell lung cancer: A retrospective analysis.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Science, Shandong First Medical University and Shandong Academy of Medical Sciences,
Abstract
Revolutionizing outcome prediction for immunotherapy with vision transformer-based pathomics signature in esophageal squamous cell cancer.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China,
Abstract
Phase I/II safety and preliminary efficacy of PM1022, a bispecific antibody targeting PD-L1 and TIGIT, in patients with advanced solid tumors.Org: Shanghai East Hospital, Tongji University, Shanghai, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Science, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China, Department of Medical Oncology, Shanghai East Hospital, School of Medicine, Tongji University,
Abstract
Updated safety and efficacy results of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) from a phase II trial.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong University of Traditional Chinese Medicine Affiliated Hospital, Shandong First Medical University and Shandong Academy of Medical Science, Jiangsu Hengrui Pharmaceuticals Co. Ltd,
Abstract
Preliminary analysis of pyrotinib and dalpiciclib-based therapy in HER2-positive advanced breast cancer (ABC).Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong University of Traditional Chinese Medicine Affiliated Hospital, Jinan, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
Concurrent durvalumab plus chemoradiation therapy followed by durvalumab in Chinese patients with unresectable stage III non-small cell lung cancer: CRUISER study.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Henan Cancer Hospital,
Abstract
The efficacy and safety of anlotinib combined with bevacizumab in treatment of recurrent isocitrate dehydrogenase wildtype glioblastoma: A retrospective analysis.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong Cancer Prevention and Treatment Research Inst, Shandong First Medical University and Shandong Academy of Medical Sciences, Department of Neurosurgery and People's Hospital of Sishui County, Shandong First Medical University and Shandong Academy of Medical Science,